Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma

Lenalidomide and dexamethasone with bortezomib (VRd) or carfilzomib (KRd) are commonly used induction regimens in the U.S. This single-center, retrospective study evaluated outcomes and safety of VRd and KRd. Primary endpoint was progression-free survival (PFS). Of 389 patients with newly diagnosed...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Blood cancer journal (New York) Ročník 13; číslo 1; s. 112 - 8
Hlavní autori:	Tan, Carlyn Rose, Derkach, Andriy, Nemirovsky, David, Ciardiello, Amanda, Diamond, Benjamin, Hultcrantz, Malin, Hassoun, Hani, Mailankody, Sham, Shah, Urvi, Maclachlan, Kylee, Patel, Dhwani, Lahoud, Oscar B., Landau, Heather J., Chung, David J., Shah, Gunjan L., Scordo, Michael, Giralt, Sergio A., Lesokhin, Alexander, Usmani, Saad Z., Landgren, Ola, Korde, Neha
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	London Nature Publishing Group UK 25.07.2023 Springer Nature B.V Nature Publishing Group
Predmet:	692/699/1541/1990/804 692/700/565/1436/1437 Antineoplastic Combined Chemotherapy Protocols - adverse effects Biomedical and Life Sciences Biomedicine Bortezomib - adverse effects Cancer Research Dexamethasone - therapeutic use Hematology Humans Immunotherapy Induction Chemotherapy Inhibitor drugs Lenalidomide - therapeutic use Multiple myeloma Multiple Myeloma - diagnosis Multiple Myeloma - drug therapy Oncology Retrospective Studies Steroids Targeted cancer therapy
ISSN:	2044-5385, 2044-5385
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!